Semaglutide copycats, Retatrutide, Tirzepatide sold without FDA approval through e-commerce
The FDA issued warning letters to seven companies for selling unapproved peptide drugs online, including products marketed as affordable alternatives to popular weight-loss medications. Guangzhou Huli Technology sold unapproved GLP-1 drugs through eBay, while Mile High Compounds in Colorado marketed GLP-1 SM, GLP-2 TRZ, and GLP-3 RT peptides. Prime Sciences sold Cagrilintide and Retatrutide without authorization.
Products claiming to contain Retatrutide, Tirzepatide, and BPC-157 were sold directly to consumers through websites, bypassing the drug approval process. Health Canada separately warned about 14 unauthorized peptide products. The FDA action targets a cottage industry selling research chemicals directly to consumers seeking cheaper alternatives to expensive prescription medications.
Consumers who purchased these products have no assurance of dosage, purity, or safety. Patients seeking weight-loss or anti-aging treatments should obtain medications only through licensed prescribers and pharmacies.
Sources
FDA Warns Co. for Unapproved GLP-1 Drug Sales on eBay
FDA Warns Mile High Compounds: Unapproved GLP-1 Drugs
FDA Warns PekCura Labs Over Unapproved GLP-1 Drugs
FDA Warns Prime Sciences: Unapproved Drug Sales Online
FDA Warns Pink Pony Peptides Over Unapproved Drugs
FDA Warns Gram Peptides Over Unapproved GLP-1 Drugs
FDA Warns FormPour for Unapproved Drug Sales Online
Health Canada Warns Against Unauthorized Peptide Drugs
Get the briefing in your inbox
The top regulatory stories, delivered daily. No noise.
Free. Unsubscribe anytime.